DRUG

apigenin

Investigational dietary flavonoid

55 hypotheses across 5 therapeutic domains

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

apigenin appears in hypotheses across 5 disease domains: ALS, Alzheimer, Epilepsy, Multiple sclerosis, Pancreatic cancer. Shared mediators that recur across at least two of those domains: GFAP, AMPK.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for apigenin

ALS 9

Mediator	Outcome	Score	Tier	Lit. status	Trial
AMPK	amyotrophic lateral sclerosis	0.269	Mid	partial evidence	none
AMPK	Alzheimer's disease	0.269	Mid	reproduces known	none
HSP90	TDP-43 proteinopathy	0.208	Mid	novel signal	none
HSP90	TDP-43 toxicity	0.208	Mid	novel signal	none
GFAP	nerve conductivity	0.208	Mid	novel signal	none
GFAP	cold pain threshold	0.208	Mid	novel signal	none
GFAP	Alexander disease	0.208	Mid	novel signal	none
GFAP	diabetic polyneuropathy	0.208	Mid	novel signal	none
GFAP	nerve amplitude	0.208	Mid	novel signal	none

Alzheimer 31

Mediator	Outcome	Score	Tier	Lit. status	Trial
GFAP	cognitive decline	0.312	High	reproduces known	none
GFAP	Alzheimer's disease	0.312	High	reproduces known	none
GFAP	cognitive impairment	0.312	High	reproduces known	none
GFAP	cognitive performance	0.269	Mid	partial evidence	none
GFAP	dementia with Lewy bodies	0.269	Mid	novel signal	none
GFAP	processing speed	0.208	Mid	novel signal	none
GFAP	AD dementia	0.208	Mid	novel signal	none
GFAP	elevated brain amyloid	0.208	Mid	novel signal	none
GFAP	FLR Aβ deposition	0.208	Mid	novel signal	none
GFAP	impaired white matter microstructure	0.208	Mid	novel signal	none
GFAP	reactive astrogliosis	0.208	Mid	novel signal	none
GFAP	neurodegeneration	0.208	Mid	reproduces known	none
GFAP	astrogliosis	0.208	Mid	partial evidence	none
GFAP	clinical Alzheimer's disease diagnosis	0.208	Mid	novel signal	none
GFAP	dementia severity	0.208	Mid	novel signal	none
GFAP	Alzheimer's disease versus behavioral-variant frontotemporal dementia	0.208	Mid	novel signal	none
GFAP	Alzheimer's disease progression	0.208	Mid	partial evidence	none
GFAP	amyloid-β pathology	0.208	Mid	novel signal	none
GFAP	Alzheimer dementia	0.208	Mid	novel signal	none
GFAP	Aβ positivity	0.208	Mid	novel signal	none
GFAP	dementia risk	0.208	Mid	novel signal	none
GFAP	somatomotor network connectivity	0.208	Mid	novel signal	none
GFAP	neuropsychological test performance	0.208	Mid	novel signal	none
GFAP	MMSE	0.208	Mid	novel signal	none
GFAP	hippocampal volume	0.208	Mid	novel signal	none
GFAP	disease progression	0.208	Mid	reproduces known	none
GFAP	brain amyloid positivity	0.208	Mid	novel signal	none
GFAP	tau-PET abnormality	0.208	Mid	novel signal	none
GFAP	executive functions	0.208	Mid	novel signal	none
GFAP	brain amyloidosis	0.208	Mid	novel signal	none
GFAP	conversion to mild cognitive impairment or dementia	0.208	Mid	novel signal	none

Epilepsy 5

Mediator	Outcome	Score	Tier	Lit. status	Trial
AMPK	epileptiform network activity	0.269	Mid	novel signal	none
AMPK	spike-wave seizures	0.269	Mid	novel signal	none
GFAP	spike frequency	0.208	Mid	novel signal	none
GFAP	injury severity	0.208	Mid	novel signal	none
GFAP	drug-resistant epilepsy	0.208	Mid	novel signal	none

Multiple sclerosis 7

Mediator	Outcome	Score	Tier	Lit. status	Trial
GFAP	confirmed disability worsening	0.269	Mid	novel signal	none
GFAP	EDSS	0.269	Mid	novel signal	none
GFAP	AQP4-NMOSD	0.269	Mid	novel signal	none
GFAP	NMOSD attacks	0.269	Mid	novel signal	none
GFAP	paramagnetic rim lesions	0.208	Mid	novel signal	none
GFAP	multiple sclerosis progression	0.208	Mid	novel signal	none
GFAP	neuropathic pain	0.208	Mid	partial evidence	none

Pancreatic cancer 3

Mediator	Outcome	Score	Tier	Lit. status	Trial
AMPK	pancreatic ductal adenocarcinoma	0.269	Mid	novel signal	none
AMPK	pancreatic cancer progression	0.269	Mid	novel signal	none
AMPK	invasion	0.269	Mid	reproduces known	none

← All drugs